Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

CollPlant Biotechnologies (CLGN) Shares Outstanding (Diluted Average) (2019 - 2024)

Historic Shares Outstanding (Diluted Average) for CollPlant Biotechnologies (CLGN) over the last 6 years, with Q4 2024 value amounting to $11.5 million.

  • CollPlant Biotechnologies' Shares Outstanding (Diluted Average) rose 57.08% to $11.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $11.5 million, marking a year-over-year increase of 57.08%. This contributed to the annual value of $11.5 million for FY2024, which is 57.08% up from last year.
  • According to the latest figures from Q4 2024, CollPlant Biotechnologies' Shares Outstanding (Diluted Average) is $11.5 million, which was up 57.08% from $11.4 million recorded in Q4 2023.
  • Over the past 5 years, CollPlant Biotechnologies' Shares Outstanding (Diluted Average) peaked at $12.0 million during Q4 2021, and registered a low of $6.9 million during Q4 2020.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $10.5 million, with a median of $11.4 million in 2023.
  • In the last 5 years, CollPlant Biotechnologies' Shares Outstanding (Diluted Average) surged by 7376.02% in 2021 and then plummeted by 780.06% in 2022.
  • Quarter analysis of 5 years shows CollPlant Biotechnologies' Shares Outstanding (Diluted Average) stood at $6.9 million in 2020, then surged by 73.76% to $12.0 million in 2021, then fell by 7.8% to $11.0 million in 2022, then rose by 3.23% to $11.4 million in 2023, then increased by 0.57% to $11.5 million in 2024.
  • Its Shares Outstanding (Diluted Average) was $11.5 million in Q4 2024, compared to $11.4 million in Q4 2023 and $11.0 million in Q4 2022.